Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

States To Pursue New Integrated Care Approaches For Dual Eligibles
As the nation debates health reform options, the Center for Health Care Strategies (CHCS) is launching Transforming Care for Dual Eligibles , a state initiative to test innovative care models for people who are dually eligible for Medicare and Medicaid ("dual eligibles"). Colorado, Maryland, Massachusetts, Michigan, Pennsylvania, Texas, and Vermont will implement strategies to improve care and control costs for dual eligibles, a high-need population with health care costs nearly five times those of other Medicare beneficiaries. The program is made possible through support from The Commonwealth Fund.
generic viagra online
Revance Therapeutics Announces Efficacy Of Topical Botulinum Toxin Type A For The Treatment Of Facial Wrinkles
Revance Therapeutics, Inc. ("Revance") announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow"s feet wrinkles, demonstrated efficacy and safety in a US Phase 2b clinical study. The randomized, double-blind, parallel-group, dose-finding study showed efficacy versus placebo at primary and multiple secondary endpoints.
News of the day
New Treatment Approach Gives Patients With Incurable Lung Cancer More Time Without Disease Progression Compared To Placebo
Results from a Phase III study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida today show that patients with advanced non-small cell lung cancer (NSCLC) who received erlotinib (Tarceva®) as first-line maintenance treatment benefited from a significant (29%) improvement in the time they lived without the disease advancing, compared with those who received placebo1. Patients in the global multicentre SATURN trial, which included patients from the UK, received maintenance treatment with erlotinib if their cancer had not progressed on initial chemotherapy. The data showed a significant improvement in the length of time patients lived without their disease getting worse, and without the need for further chemotherapy. 1 The improvement was seen in both of the main types of NSCLC (squamous cell as well as non-squamous cell) and these results form the basis of a submission for regulatory approval of erlotinib to be used in the first-line maintenance setting. 1 Erlotinib is not currently licensed for first line maintenance treatment in NSCLC lung cancer in the UK.
Diagnostics

Removal Of Ban On Federal Funding For Needle Exchange Programs To Be Debated In Congress

An amendment to the fiscal year 2010 appropriations bill for health, labor and education programs that opposes the lifting of the ban on federal funding for needle exchange programs will come to the House floor for debate today along with four others, CQ Today reports. Rep. Mark Souder (R-Ind.) "will offer an amendment to strip language that would lift the ban on federal funding for needle exchange programs," CQ writes. According to CQ Today, "Conservatives are concerned that eliminating the ban on federal funds for such programs, which are designed to reduce the transmission of HIV and other diseases, would be tantamount to helping fund addicts" drug habits. Democrats say science has shown that such programs, when coupled with comprehensive prevention strategies, can reduce the rate of [HIV] infections and do not promote drug use." House Appropriations Committee Chair David Obey (D-Wis.) "added compromise language in the committee this week that would prohibit funds from going to needle exchange programs within 1,000 feet of facilities that serve children, such as schools and parks," the article states. The House is expected to vote on the amendment and the appropriations bill today (Wolfe, 7/23). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009